Sun Pharma gets DCGI nod to make, mkt generic semaglutide injection in India
This story was originally published at 09:15 IST on 23 January 2026
Register to read our real-time news.Informist, Friday, Jan. 23, 2026
--Sun Pharma gets DCGI OK to make, market generic semaglutide in India
MUMBAI – Sun Pharmaceutical Industries Ltd. Friday said it has received approval from the Drugs Controller General of India to manufacture and market a generic form of semaglutide injection. Sun Pharma will launch generic semaglutide injection under the brand name Noveltreat following the expiry of semaglutide patent in India, according to an exchange filing by the company.
Noveltreat will be available in five dose strengths ranging from 0.25 milligram or 0.5 millilitres to 2.4 milligram or 0.75 millilitres, with a maintenance dose of 2.4 milligram once weekly, according to the filing. The product is in the form of a prefilled pen. Semaglutide is a glucagon-like peptide-1 receptor agonist and is used for chronic weight management in adults.
In December, Sun Pharma received DCGI approval for manufacturing and marketing semaglutide injections for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. It will be launched under the brand name Sematrinity, after the expiry of the semaglutide patent in India.
For the quarter ended September, the company reported a consolidated net profit of INR 31.18 billion on a revenue of INR 144.78 billion. Thursday, shares of the company ended over 1% higher at INR 1,634.20 on the National Stock Exchange. End
Reported by Eshitva Prakash
Edited by Vandana Hingorani
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
